Covance Epidemiologist Appointments Further Strengthen Risk Management and Periapproval Services to Biopharmaceutical Companies
— Epidemiologists Bring More Than 20 Years Combined Experience in Epidemiology, Clinical Research, Clinical and Observational Trials —

Princeton, New Jersey, September 26, 2006 — Covance Inc. (NYSE: CVD), one of the world's largest and most comprehensive drug development services companies, today announced the appointment of two new epidemiologists, Paige Chavers, MSPH, BSN, and Zdravko Vassilev, M.D., MPH, who join the Covance Periapproval team to provide scientific and technical support in epidemiology, clinical outcomes, and risk management.

The addition of Ms. Chavers and Dr. Vassilev to the epidemiology team will further support the continued growth of Covance Periapproval Services. Together they have more than 20 years of combined experience in epidemiology, clinical research, and clinical and observational trials.

"In addition to strengthening our periapproval team, Ms. Chavers and Dr. Vassilev provide further support to our overall Risk Management expertise and service offering as well as our commitment to patient safety," said Jeffrey Stoddard, M.D., Vice President, Medical and Scientific Affairs, Risk Management and Post-Marketing Solutions. "In gaining additional expertise which blends medical insight with epidemiology training, we continue to strengthen our ability to offer solutions for real world settings."

Ms. Chavers brings extensive experience in epidemiology, most recently serving as a Clinical Project Specialist with Schering-Plough where she managed clinical trials and study projects as part of Schering-Plough Research Institute-sponsored studies. During her career, Ms. Chavers has worked on multiple Phase IV observational programs spanning numerous therapeutic areas. Ms. Chavers is a registered nurse and holds a master's degree in public health from the University of Alabama-Birmingham.

Dr. Vassilev brings significant experience to Covance in the areas of epidemiologic and clinical research and observational analytic epidemiology. He holds a doctorate degree in medicine from Pavlov University in Bulgaria, a master's degree in public health from Emory University and completed a post-doctoral fellowship in health indicators at Rutgers University. Dr. Vassilev most recently served as an Epidemiologist for the New Jersey Poison Control Center where he provided epidemiologic expertise including study conceptualization and design, data collection, analysis, interpretation and dissemination. As Principal Research Associate with the Institute for Treatment and Services Research, Dr. Vassilev worked on projects in the areas of substance abuse, Hepatitis C, HIV/AIDS, and health services research, and holds appointments as Assistant Professor in the New Jersey Medical School and the School of Public Health.

About Covance Risk Management and Periapproval Program Services
Risk management is the ongoing process of assessing and mitigating the impact of risk throughout a product's lifecycle — from non-clinical testing to clinical trials to post marketing surveillance. With more than 40 years of experience in drug development, Covance provides an unparalleled breadth of expertise and resources to help biopharmaceutical clients meet their risk management goals across the drug development continuum.

Covance designs and implements postapproval risk minimization programs that optimize product safety and effectiveness; addressing unanswered safety questions, meeting regulatory requirements, confirming and validating effectiveness in real-world use, better defining the safety profile and providing a cornerstone for Risk Management. Covance scientific and operations teams work with biopharmaceutical clients to determine the best solution for desired outcomes, designing unique solutions for risk management and evaluation, from design through execution, analysis and reporting.

About Covance
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in more than 20 countries, and greater than 7,900 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at

Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to an qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.

Covance and the Covance are registered service marks of Covance in the United States and other countries.